Return to Projects Page.
Genotyping is a process in which an individual’s DNA is examined to reveal specific traits and
alleles. Within the eMERGE Network all participants are genotyped by individual sites, and this individual level
data is then combined to create a de-identified dataset used for analysis. All data are sent through a strict quality
control protocol and imputed to guarantee consistency and quality. The Genomics Workgroup handles all GWAS
data QC and analysis. The Network uses the Illumina 660W platform for Caucasian
cohorts and the Illumina 1M platform for the (QRS) and Type 2 Diabetes (T2D) African American cohorts. Additional
genotyping efforts have focused on pharmacogenomic specific samples and the identification of null
variants within the main eMERGE dataset.
Data Set Counts
For additional details on the platforms used in the eMERGE data sets please click here.
Data Counts by Site
- Crosslin DR, Tromp G, Burt A, Kim DS, Verma SS…de Andrade M. Controlling for population structure and genotyping platform bias in the eMERGE multi-institutional biobank linked to Electronic Health Records. Front Genet. 2014 Nov 4;5:352. PMID: 25414722
- Meng XR, Song JY, Ma J, Liu FH…Wang HJ. Association study of childhood obesity with eight genetic variants recently identified by genome-wide association studies. Pediatr Res. 2014 Sep;76(3):310-5. PMID: 24956226
- Williams SM. Identifying population differences in genes that affect body mass index. Genome Med. 2013; 5(11): 102. PMCID: 3978763
- Null Variants
*Click here to view a listing of eMERGE Studies currently available in dbGaP.